Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Given Average Rating of “Reduce” by Brokerages

Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) have been assigned a consensus rating of “Reduce” from the twelve ratings firms that are currently covering the firm, MarketBeat reports. Four research analysts have rated the stock with a sell rating, seven have given a hold rating and one has assigned a buy rating to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $8.20.

Several equities analysts have issued reports on FULC shares. JPMorgan Chase & Co. cut shares of Fulcrum Therapeutics from an “overweight” rating to an “underweight” rating in a research note on Wednesday, June 3rd. Wall Street Zen upgraded shares of Fulcrum Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 2nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Fulcrum Therapeutics in a report on Friday, July 17th. Truist Financial lowered shares of Fulcrum Therapeutics from a “buy” rating to a “hold” rating and set a $4.00 price target on the stock. in a research note on Tuesday, June 2nd. Finally, HC Wainwright cut shares of Fulcrum Therapeutics from a “buy” rating to a “neutral” rating and set a $3.00 price target for the company. in a report on Tuesday, June 2nd.

Insider Activity

In other news, Director Alan Ezekowitz sold 18,000 shares of the stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $3.65, for a total transaction of $65,700.00. Following the completion of the transaction, the director directly owned 10,927 shares of the company’s stock, valued at approximately $39,883.55. This represents a 62.23% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 7.30% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of FULC. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Fulcrum Therapeutics in the 4th quarter valued at about $30,000. Meeder Asset Management Inc. purchased a new position in Fulcrum Therapeutics during the 4th quarter valued at about $39,000. Quarry LP purchased a new position in shares of Fulcrum Therapeutics during the 3rd quarter worth approximately $35,000. Persistent Asset Partners Ltd acquired a new position in shares of Fulcrum Therapeutics in the fourth quarter worth $75,000. Finally, Summit Securities Group LLC acquired a new position in Fulcrum Therapeutics in the 1st quarter valued at about $53,000. Institutional investors and hedge funds own 89.83% of the company’s stock.

Fulcrum Therapeutics Trading Down 0.3%

Shares of FULC stock opened at $3.71 on Friday. The company has a market capitalization of $283.07 million, a P/E ratio of -3.07 and a beta of 3.05. The business’s 50 day moving average is $3.67 and its two-hundred day moving average is $6.48. Fulcrum Therapeutics has a twelve month low of $2.83 and a twelve month high of $15.74.

Fulcrum Therapeutics (NASDAQ:FULC) last released its quarterly earnings results on Thursday, July 30th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.10). As a group, equities analysts predict that Fulcrum Therapeutics will post -0.69 earnings per share for the current fiscal year.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small?molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.